Clinical and immunologic aspects of cancer-associated retinopathy

Ohguro, Hiroshi; Yokoi, Yuki; Ohguro, Ikuyo; Mamiya, Kazuhisa; Ishikawa, Futoshi; Yamazaki, Hitoshi; Metoki, Tomomi; Takano, Yoshiko; Ito, Tadashi; Nakazawa, Makoto

doi:10.1016/j.ajo.2004.01.010

Cited by 91 publications

(60 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Symptoms are typically worse than the clinical signs, and the fundus frequently appears normal [14]. Retinal arteriole attenuation and waxy optic disc pallor develop later in some cases [14], and iritis and vitritis have also been reported in a few patients [16]. Diagnosis involves the exclusion of genetic retinal dystrophies or any medical cause for the retinopathy (pseudo-retinitis pigmentosa and drug toxicity).…”

Section: Clinical Phenotypesmentioning

confidence: 99%

“…Recoverin is expressed by numerous tumours [5], and antirecoverin retinopathy has been associated with various cancers including small-cell lung [34], cervical [35] and endometrial carcinomas [36], uterine sarcoma [37] and mixed Mullerian tumour [38]. The clinical phenotype most frequently reported with antirecoverin-associated CAR is that of aggressive, severe rod and cone dysfunction and marked vision loss, to no perception of light in some cases [16,34,39]. Anti-recoverin antibodies were once thought to be sensitive [16] and specific [13] to CAR, and have not been identified in npAIR [13], but were recently found in 5 out of 521 patients with retinitis pigmentosa [27].…”

Section: Antigens and Antibodiesmentioning

confidence: 99%

“…The clinical phenotype most frequently reported with antirecoverin-associated CAR is that of aggressive, severe rod and cone dysfunction and marked vision loss, to no perception of light in some cases [16,34,39]. Anti-recoverin antibodies were once thought to be sensitive [16] and specific [13] to CAR, and have not been identified in npAIR [13], but were recently found in 5 out of 521 patients with retinitis pigmentosa [27]. …”

Section: Antigens and Antibodiesmentioning

confidence: 99%

See 2 more Smart Citations

Autoimmune Retinopathy

Braithwaite

Vugler²,

Tufail

2012

Ophthalmologica

View full text Add to dashboard Cite

Autoimmune retinopathy encompasses a spectrum of rare autoimmune diseases that primarily affect retinal photoreceptor function, and include cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR) and presumed non-paraneoplastic autoimmune retinopathy (npAIR). Autoimmune retinopathy typically presents in the fifth and sixth decades with rapidly progressive, bilateral, painless visual deterioration but an unremarkable fundus examination. CAR, MAR and npAIR have an overlapping clinical phenotype, and extensive investigation is required to exclude other causes of retinopathy, and to identify any occult malignancy, before a presumptive diagnosis can be made. Delayed diagnosis, and treatment initiation relatively late in the disease course, may contribute to the poor visual prognosis. Various treatments have been attempted, including systemic immunosuppression with steroid and steroid-sparing agents, intravenous immunoglobulin, and plasmapheresis, but these lack an evidence base. A variety of antiretinal antibodies have been identified in patients with autoimmune retinopathy, including antibodies to recoverin, α-enolase and transducin-α, but seronegative disease is also common. Clinical access to specialised serological investigation is very limited internationally, and this exacerbates the management challenge presented by patients with suspected autoimmune retinopathy. Several decades of experimental research have resulted in very considerable advances in our understanding of the pathophysiological mechanisms that may underlie autoimmune retinopathy. However, the precise triggers which result in loss of ocular immune privilege and sudden autoimmune attack on retinal cells have yet to be elucidated. This review summarizes the classification, investigation and management of autoimmune retinopathy, and considers the evolving concepts about its immunological aetiology.

show abstract

Section: Clinical Phenotypesmentioning

confidence: 99%

Section: Antigens and Antibodiesmentioning

confidence: 99%

Section: Antigens and Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Autoimmune Retinopathy

Braithwaite

Vugler²,

Tufail

2012

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Akciğer kanseri ile ilişkili paraneoplastik hastalıklar, sinir sisteminin santral ya da periferik kısmını etkileyebilir. Paraneoplastik multifokal ensefalomiyelit, paraneoplastik limbik ensefalit, serebellar dejenerasyon, opsoklonus-myoklonus sendromu ve daha seyrek gözlenen ancak %75 KHAK birlikteliği bilinen paraneoplastik retinopatiler gibi santral PNH ile, periferik PNH içinde yer alan subakut duyusal nöropati, LEMS, dermatomiyozit varlığının saptanması akciğer kanseri varlığı açısından güçlü göstergelerdir (32,33).…”

Section: Paraneoplasti̇k Nöroloji̇k Hastaliklarunclassified

Neurologıc Problems Accompanyıng Lung Cancer

Aydın¹,

Sohtaoğlu²

2016

Toraks Cer Bult

View full text Add to dashboard Cite

Neurological problems that may occur in lung cancer are caused by both the cancer and treatment to be applied. Intracranial and extracranial nervous system metastases, cerebrovascular diseases, paraneoplastic neurologic disorders and treatment-induced peripheral and central nervous system diseases can be observed during diagnosis and treatment. The most common neurological problems of lung cancer are intracranial brain metastases. Making early diagnosis and administering treatment by considering the neurological symptoms in follow-up patients are important for both in terms of long-term preservation of neurological function of the patients and to provide longer survival.

show abstract

“…[54][55][56] Other autoantibody targets that have been proposed to play a role in AIR include transducin-β, transducin-α, neurofilament protein, photoreceptor cell-specific nuclear receptor, Muller cell-specific antigen, transient receptor potential cation channel, subfamily M, member 1 (TRPM1), and a number of yet unidentified putative antigen targets. 10,11,57 Unfortunately, there are no in vitro or in vivo studies to support the pathogenicity of any of these autoantibodies in AIR.…”

Section: Antiretinal Antibodies: Pathogenic Uncertaintiesmentioning

confidence: 99%